

Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy

NCT07220785

Status	RECRUITING
Phase	Phase 3
Sponsor	Regeneron Pharmaceuticals
Enrollment	28 participants

Key Eligibility Criteria

Inclusion (12)

- \. Diagnosis of congenital or acquired GLD as defined by Multi-Society Practice Guidelines
- For Part A only:
- Participants e2 years of age at screening
- At least one of the below criteria are fulfilled during screening (measurements can be repeated once during screening period)
- HbA1c e7%

... and 7 more (see full listing online)

Exclusion (10)

- Has a current diagnosis of familial or acquired partial lipodystrophy or autoimmune (Type 1) diabetes mellitus
- Any malignancy, eg, lymphoma, within the past 1 year, prior to screening visit, as described in the protocol
- eGFR of \<30 mL/min/1.73 m² based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine or Schwartz equation, as applicable, at screening. Assessment can be repeated once
- History of heart failure hospitalization, diagnosis of a myocardial infarction, stroke, clinically significant arrhythmia, as described in the protocol
- Treatment with over-the-counter or prescription medications with the intention of weight loss within 3 months prior to the screening visit

... and 5 more (see full listing online)

Locations (1 total)

University of Michigan, Ann Arbor, Michigan, United States